Renal Biomarker

Renal Biomarker

Global Renal Biomarkers Market to Reach $1.5 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Renal Biomarkers estimated at US$937.6 Million in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027. Functional Biomarkers, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$810.1 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Up-Regulated Proteins segment is readjusted to a revised 6.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $271.2 Million, While China is Forecast to Grow at 6% CAGR

The Renal Biomarkers market in the U.S. is estimated at US$271.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$254.5 Million by the year 2027 trailing a CAGR of 5.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Other Biomarkers Segment to Record 4.9% CAGR

In the global Other Biomarkers segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$87.3 Million in the year 2020 will reach a projected size of US$122.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 44 Featured) -

  • Abbott Molecular, Inc.
  • Astute Medical, Inc.
  • Beckman Coulter, Inc.
  • BioPorto Diagnostics A/S
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Renal Biomarker – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Renal Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Renal Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Renal Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Functional Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Functional Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for Functional Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Up-Regulated Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Up-Regulated Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Up-Regulated Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 10: World Recent Past, Current & Future Analysis for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Other Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for Enzyme Linked Immunosorbent Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Enzyme Linked Immunosorbent Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Enzyme Linked Immunosorbent Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 16: World Recent Past, Current & Future Analysis for Particle-Enhanced Turbidimetric Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Particle-Enhanced Turbidimetric Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Particle-Enhanced Turbidimetric Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 19: World Recent Past, Current & Future Analysis for Colorimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Colorimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 21: World 15-Year Perspective for Colorimetric Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 22: World Recent Past, Current & Future Analysis for Chemiluminescent Enzyme Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 23: World Historic Review for Chemiluminescent Enzyme Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 24: World 15-Year Perspective for Chemiluminescent Enzyme Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 25: World Recent Past, Current & Future Analysis for Liquid Chromatography-Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 26: World Historic Review for Liquid Chromatography-Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 27: World 15-Year Perspective for Liquid Chromatography-Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 28: World Recent Past, Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 29: World Historic Review for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 30: World 15-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 31: World Recent Past, Current & Future Analysis for Outpatient Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 32: World Historic Review for Outpatient Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 33: World 15-Year Perspective for Outpatient Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 34: World Recent Past, Current & Future Analysis for Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 35: World Historic Review for Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 36: World 15-Year Perspective for Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 37: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 38: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 39: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 40: World Renal Biomarker Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027
III. MARKET ANALYSIS
UNITED STATES
Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
TABLE 41: USA Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 42: USA Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 43: USA 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 44: USA Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 45: USA Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 46: USA 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 47: USA Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 48: USA Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 49: USA 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
CANADA
TABLE 50: Canada Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 51: Canada Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 52: Canada 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 53: Canada Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 54: Canada Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 55: Canada 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 56: Canada Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 57: Canada Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 58: Canada 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
JAPAN
Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
TABLE 59: Japan Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 60: Japan Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 61: Japan 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 62: Japan Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 63: Japan Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 64: Japan 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 65: Japan Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 66: Japan Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 67: Japan 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
CHINA
Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
TABLE 68: China Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 69: China Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 70: China 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 71: China Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 72: China Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 73: China 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 74: China Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 75: China Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 76: China 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
EUROPE
Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
TABLE 77: Europe Recent Past, Current & Future Analysis for Renal Biomarker by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 78: Europe Historic Review for Renal Biomarker by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 79: Europe 15-Year Perspective for Renal Biomarker by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
TABLE 80: Europe Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 81: Europe Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 82: Europe 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 83: Europe Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 84: Europe Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 85: Europe 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 86: Europe Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 87: Europe Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 88: Europe 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
FRANCE
Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
TABLE 89: France Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 90: France Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 91: France 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 92: France Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 93: France Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 94: France 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 95: France Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 96: France Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 97: France 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
GERMANY
Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
TABLE 98: Germany Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 99: Germany Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 100: Germany 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 101: Germany Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 102: Germany Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 103: Germany 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 104: Germany Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 105: Germany Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 106: Germany 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
ITALY
TABLE 107: Italy Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 108: Italy Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 109: Italy 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 110: Italy Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 111: Italy Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 112: Italy 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 113: Italy Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 114: Italy Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 115: Italy 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
UNITED KINGDOM
Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
TABLE 116: UK Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 117: UK Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 118: UK 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 119: UK Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 120: UK Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 121: UK 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 122: UK Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 123: UK Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 124: UK 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
REST OF EUROPE
TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 126: Rest of Europe Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 127: Rest of Europe 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 129: Rest of Europe Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 130: Rest of Europe 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 132: Rest of Europe Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 133: Rest of Europe 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Renal Biomarker Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 135: Asia-Pacific Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 136: Asia-Pacific 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 138: Asia-Pacific Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 139: Asia-Pacific 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 141: Asia-Pacific Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 142: Asia-Pacific 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
REST OF WORLD
TABLE 143: Rest of World Recent Past, Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 144: Rest of World Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 145: Rest of World 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2021 & 2027
TABLE 146: Rest of World Recent Past, Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 147: Rest of World Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 148: Rest of World 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2021 & 2027
TABLE 149: Rest of World Recent Past, Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 150: Rest of World Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 151: Rest of World 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2021 & 2027
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings